ESPR Esperion Therapeutics Inc.

38.89
+0.61  (+2%)
Previous Close 38.28
Open 38.32
Price To Book 4.87
Market Cap 1041691867
Shares 26,785,597
Volume 966,567
Short Ratio 2.6
Av. Daily Volume 1,517,967

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released March 27, 2018. Primary endpoint met. LDL-C lowering 30%.
Bempedoic Acid - 1002-039
Hypercholesterolemia
Phase 3 initiation announced November 6, 2017. Data due August 2018.
Bempedoic Acid/ Ezetimibe (1002FDC-053)
Hypercholesterolemia
Phase 2 (PK/PD) top-line data met primary endpoint - October 2016.
Bempedoic acid (ETC-1002-035)
Patients treated with high-dose statin therapy
Phase 3 data released May 23, 2018 - primary endpoint met. No fatal events. Discontinuation due to AE was greater than placebo.
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046
Hypercholesterolemia - statin intolerance
Phase 3 long-term safety and tolerability data released May 2, 2018. Primary endpoint met but high number of deaths vs placebo.
Bempedoic acid (ETC-1002-040) - Clear Harmony
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 3 data released March 7, 2018.
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-048
Hypercholesterolemia
Phase 3 data due September, 2018.
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-047
Hypercholesterolemia

Latest News

  1. IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
  2. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018 - ESPR
  3. ESPR NOTICE: Rosen Law Firm Reminds Esperion Therapeutics, Inc. Investors of Important Upcoming Deadline in Class Action – ESPR
  4. EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018 - ESPR
  5. Stock Performance Review on Exelixis and Three Other Biotech Stocks
  6. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ESPR
  7. Kessler Topaz Meltzer & Check, LLP Announces Class Action Lawsuit Filed Against Esperion Therapeutics, Inc. on Behalf of Investors
  8. SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Class Actions Involving Molina Healthcare, Inc., Esperion Therapeutics, Inc., PPG Industries, Inc., Prothena Corporation, and Fluor Corporation
  9. INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Esperion Therapeutics, Inc. (ESPR) & Lead Plaintiff Deadline - July 6, 2018
  10. The Klein Law Firm Reminds Investors of Class Actions Commenced on Behalf of Shareholders of Molina Healthcare, Inc., Esperion Therapeutics, Inc., Kulicke and Soffa Industries, Inc., and PPG Industries, Inc.
  11. Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Esperion Therapeutics, Inc. (ESPR) and Encourages Investors to Contact the Firm
  12. ESPR NOTICE: Pawar Reminds of Important July 6, 2018 Lead Plaintiff Deadline in Esperion Therapeutics, Inc. Class Action - ESPR
  13. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018 – ESPR
  14. Kessler Topaz Meltzer & Check, LLP - Deadline Reminder for Esperion Therapeutics, Inc. Investors – ESPR
  15. ESPR NOTICE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Esperion Therapeutics, Inc. - ESPR
  16. Esperion Announces Late-Breaking Oral Presentation of Full Study 4 Results (1002-048) at the International Symposium on Atherosclerosis